Friday, November 13, 2026

Tesla Stock Jumped 3.55% on Wednesday: Will it Correct on The Next Session?

ViaNews Editorial Team

November 26, 2020

Tesla Stock Jumped 3.55% on  Wednesday: Will it Correct on The Next Session?
Tesla shares jumped 3.35% to $574.00 at yesterday, The Nasdaq Stock Market is rose 0.48% to $12,094.40. According to tuesday's article on Bloomberg Quint, "Nikola, Tesla Shares Fall as EV Rally Frenzy Comes to a Halt." According to Tuesday's article on MarketWatch, "Tesla issues recall of 9,000-plus Model X and Model Y vehicles." Tesla's last close was $555.38, 0.05% under its 52-week high of $573.70. Tesla's sales growth is 35.3% for the ongoing quarter and 60% for the next. The company's growth estimates for the ongoing quarter and the next is 112.2% and 265.2%, respectively. Year-on-year quarterly revenue growth grew by 39.2%, now sitting on 28.18B for the twelve trailing months. Tesla's stock is valued at $574.00 at 08:26 EST, above its 52-week high of $573.70. Tesla's worth is way higher than its 50-day moving average of $435.96 and way higher than its 200-day moving average of $332.14. Tesla-heavy etfs ride along as company gets a price upgrade. According to MarketWatch on Mon Nov 23, "Exchovere-traded funds with heavy exposure to Tesla Inc." According to Bloomberg Quint on Tue Nov 24, "Musk Hints Again at Longer-Range Teslas and Hatchback for Europe." According to Bloomberg Quint on Tue Nov 24, "Tesla Nears Half a Trillion Mark After Soaring 525% This Year."
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com